Our findings suggest that KLF2 may inhibit tumor angiogenesis and growth in breast cancer by inhibiting the VEGFA-HIF pathway, and thus KLF2 may be an important anti-angiogenesis therapeutic target for breast cancer. This evidence concerns the gene KLF2 and breast carcinoma.